Callisto Pharmaceuticals, Incorporation - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Callisto Pharmaceuticals, Incorporation. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Callisto Pharmaceuticals, Incorporation. The Group's principal activity is developing drugs to treat relapsed acute leukemia, multiple myeloma, and advanced carcinoid cancer patients. Its drug candidate, L-Annamycin, a drug from the anthracycline family completed an initial Phase I/IIa clinical trial. Its second drug candidate, Atiprimod, is an orally administered drug with antiproliferative and antiangiogenic activity completed a Phase I/IIa clinical trial. The company is in a development stage and its operations are located in the United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report